Alex A. Adjei is the recipient of the 2021 ESMO Lifetime Achievement Award

Prof. Dr. Alex A. Adjei, Chairman of the Oncology Advisory Committee of Swiss Rockets, has been named as the recipient of the 2021 ESMO Lifetime Achievement Award. This extraordinary recognition of his accomplishments follows his 2020 Adi F. Gazdar IASLC Merit Award. The prestigious ESMO Lifetime Achievement Award was established in 2006 to recognize international [...]

By |2021-08-12T13:25:38+01:0012th August, 2021|Press Release|

RocketVax successfully raises CHF 7.2 million of seed funding

RocketVax has successfully secured CHF 7.2 million in its Seed A financing to fund the pre-clinical development of its Covid-19 vaccine. Renowned institutional and private investors have funded this financing round. RocketVax is now launching the Seed B financing to fund the first phase of clinical development in humans. RocketVax AG is pleased to announce [...]

By |2021-08-03T15:35:10+01:003rd August, 2021|Press Release|

Batavia Biosciences to develop innovative clinical process for RocketVax’s second generation COVID-19 vaccine

Today, Batavia Biosciences announces their collaboration with RocketVax, a subsidiary of Swiss Rockets AG developing vaccines based on breakthrough genetic engineering. Under the agreement, Batavia will develop the clinical process and deliver clinical product of RocketVax’s vaccine candidate against the SARS-CoV-2 virus. RocketVax is developing a promising second generation COVID-19 vaccine candidate, called RVX-13 which, [...]

By |2021-08-12T13:21:11+01:006th July, 2021|Press Release|

Basel government approves one million for research to develop novel vaccine against SARS-CoV-2 coronavirus

Basel University Hospital, the University of Basel and the Swiss Tropical and Public Health Institute have agreed to collaborate with the company RocketVax and jointly advance research to develop a novel vaccine against the SARS-CoV-2 coronavirus. The University Hospital Basel (USB), the University of Basel and the Swiss Tropical and Public Health Institute (Swiss TPH) [...]

By |2021-06-18T09:22:13+01:0017th June, 2021|Press Release|

RocketVax AG and Swiss Rockets AG expand science and leadership teams

RocketVax AG and Swiss Rockets AG have recruited additional experts to join their scientific and leadership teams to accelerate the development of the SARS-CoV-2 vaccine RVX-13 and to position the companies for the future. Swiss Rockets AG founded the subsidiary RocketVax AG in 2020 to develop a next-generation vaccine against SARS-CoV-2 (RVX-13). To accelerate the [...]

By |2021-06-03T15:01:52+01:003rd June, 2021|Press Release|

Innosuisse supports the Basel biotech company RocketVax in its research into the second generation of SARS-CoV-2 vaccines

When the ongoing coronavirus pandemic broke out at the start of 2020, Swiss Rockets AG set itself the challenge of manufacturing a vaccine that activates multiple lines of immune system defense to combat SARS-CoV-2 most effectively. To achieve this mission, it founded the Basel-based subsidiary RocketVax AG in the summer of 2020. To start working [...]

By |2021-04-19T13:39:52+01:0016th April, 2021|Press Release|

Prof. Dr. med. Alex A. Adjei, Chairman of the Oncology Advisory Committee of Swiss Rockets, is the 2020 Adi F. Gazdar IASLC Merit Award Recipient

Prof. Dr. Alex A. Adjei has been chosen as the inaugural recipient of the Adi F. Gazdar IASLC Merit Award. For his many accomplishments and a passion for cancer drug development, as well as for mentoring the next generation of specialists during his multifaceted career, Prof. Dr. Adjei has been selected for the award by [...]

By |2021-02-10T16:42:57+01:0010th February, 2021|Press Release|

Swiss Rockets AG announces the founding of ROCKETVAX for the development of a next-generation SARS-CoV-2 vaccine

The rapid development of an effective and safe vaccine against SARS-CoV-2 is a top priority for Swiss Rockets AG. A Basel-based subsidiary, RocketVax AG, was founded to utilize innovative Swiss technologies and expertise to achieve this goal. "The development of a SARS-CoV-2 vaccine might be more complex than anticipated, and the first generation of vaccines [...]

By |2020-11-16T09:43:59+01:0010th November, 2020|Press Release|

The biotech company Swiss Rockets AG enters into a strategic partnership with daura AG – the Swiss platform for digital stocks

The collaboration between Swiss Rockets and daura is designed to facilitate the financing of promising life science projects. With the daura platform, investments in biotech start-ups will be possible digitally even with smaller amounts and without transaction costs. By selecting research projects in oncology and immunology, the biotech company Swiss Rockets supports a paradigm shift, [...]

By |2020-08-28T08:23:01+01:0027th August, 2020|Press Release|

Swiss Rockets AG has assembled an Advisory Committee of renowned Oncology scientists to help it develop new cancer treatments

Inspired by cancer patients and dedicated to their well-being, Swiss Rockets provides access to innovative anti-cancer treatments. Internationally recognized experts of the Oncology Advisory Committee accelerate and secure drug discovery programs as well as advise and lead clinical development of the most promising technologies.   Prof. Dr. med. Alex A. Adjei, Chairman of Oncology Advisory [...]

By |2020-06-09T08:28:22+01:005th June, 2020|Press Release|